These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.The company's revenue came in at $2.97 billion versus estimates of $2.90 billion. Adjusted EPS came in at $4.52, versus estimates of $4.29."Vertex delivered a strong quarter of revenue growth with each of our three product launches — ALYFTREK, JOURNAVX and CASGEVY — contributing, as well as continued advancement of our clinical programs," said Reshma Kewalramani, president and CEO o ...